Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
PRNewswire - 22 February 2002
The UDMYV recalls offers from international companies and other donors, to sponsor the provision of antiretroviral drugs. In fact, Boehringer-Ingelheim, which for two years has tried unsuccessfully to persuade the government to accept its free offer of Nevirapine, just yesterday said it does not intend to give up.
Kevin McKenna of Boehringer-Ingelheim was quoted saying "When we first offered the drug it was meant for the whole world as it still is now. Rejection won't make us change that policy; we still want to provide the medicine. Should they (the Health Department) approach us we will be glad to enter into negotiations with them."
Although Minister Manuel has announced a large increase in the budget for spending on South Africa's fight against HIV/Aids, the UDMYV hopes that these funds will be properly administered and successfully and effectively used.
Unfortunately provincial governments have proven their inability to spend the money allocated to them for the fight against HIV/Aids and the UDMYV calls on government to ensure that these desperately needed funds benefit those who it was intended for; those who suffer from this terrible illness and their families, friend and community who suffer with them and to motivate, through HIV/Aids education, each and every South African to treat themselves and others with respect.
The UDMYV calls on the Ministers of Health and Finance to immediately contact companies, like, Boehringer-Ingelheim, and enter negotiations to facilitate the provision of antiretroviral drugs, in order to save money and so ensure that the budget is properly divided into all priority areas.
Enquiries:
Mr Luzuko Luwaca
Secretary General UDMYV
+27 (0)82 965 7879
UDM National Office - Pretoria
(t) +27 (0)12-321-0010
(f) +27 (0)12-321-0014
Please visit the UDM website - www.udm.org.za for more information on the UDM and the latest press releases PR Newswire disclaims all liability for any loss, damage, injury or expense however caused, arising from the use of or reliance upon, in any manner, the information provided through this service and does not warrant the truth, accuracy or completeness of the information provided.
020222
PR020235
Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .